Status: Not yet recruiting

Adebrelimab Combined With SHR2554 in Relapsed/Refractory PTCL and NK/T-Cell Lymphoma

To evaluate the safety of adebrelimab combined with SHR2554 in the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL) and NK/T-cell lymphoma (NKTCL), to determine the recommended Phase 2 dose (RP2D) of the combination regimen, and to assess preliminary efficacy.

Participants needed: 40

Trial details

Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Sun Yat-sen UniversityUpdated: May 29, 2026Locations: 1

Eligibility criteria

Age ≥18 years old,regardless of gender; [+20]

Pregnant or lactating women; [+26]

Status: Not yet recruiting

A Phase II Study of Sintilimab, Pegaspargase and Selinexor Followed by Radiotherapy in Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma

This is a single-arm, open-label, multicenter phase II study evaluating sintilimab, pegaspargase, and selinexor followed by radiotherapy as first-line treatment for patients with newly diagnosed stage I/II extranodal natural killer/T-cell lymphoma (ENKTL).

Participants needed: 47

Trial details

Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Sun Yat-sen UniversityUpdated: May 8, 2026Locations: 1

Eligibility criteria

Age 18 years or older. [+8]

Aggressive NK-cell leukemia. [+4]

Status: Recruiting

"Selinexor+Pegaspargase+Dexamethasone"in Ⅰ/Ⅱ NKTCL

evaluate the efficacy and safety of "Selinexor+pegaspargase+dexamethasone" in early stage NK/ T-cell lymphoma

Participants needed: 50

Trial details

Phase: Phase 1, Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: Mingzhi ZhangUpdated: Jul 14, 2025Locations: 1

Eligibility criteria

Age 18-70 years old, ECOG score 0-2; (including those aged 18 and 70); [+9]

Refuse to collect blood samples; [+12]